Atossa Therapeutics Inc
NASDAQ:ATOS
Atossa Therapeutics Inc
NASDAQ:ATOS
Price:
5.42
USD
-1.63%
Market Cap:
$46.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Atossa Therapeutics Inc
NASDAQ:ATOS
|
US |
|
A
|
ACS Actividades de Construccion y Servicios SA
VSE:ACS
|
ES |
|
S
|
Suzhou YourBest New-type Materials Co Ltd
SZSE:301266
|
CN |
|
L
|
Laguna Resorts and Hotels PCL
SET:LRH
|
TH |
|
T
|
Topaz Energy Corp
TSX:TPZ
|
CA |
|
M
|
Marinomed Biotech AG
VSE:MARI
|
AT |
|
Aksh Optifibre Ltd
NSE:AKSHOPTFBR
|
IN |
|
Al Gassim Investment Holding Company SJSC
SAU:6020
|
SA |
|
Nan Ya Printed Circuit Board Corp
TWSE:8046
|
TW |
|
Carlisle Companies Inc
NYSE:CSL
|
US |
|
Weave Communications Inc
NYSE:WEAV
|
US |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of ATOS.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ATOS
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
ATOS Competitors Multiples
Atossa Therapeutics Inc Competitors
Atossa Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Atossa Therapeutics Inc
NASDAQ:ATOS
|
46.7m USD | 0 | -1.5 | 0.2 | 0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6.1 | 89.1 | 14.8 | 20.5 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.4B USD | 6.2 | -96.2 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20.1 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.7 | 29.3 | 22.1 | 23.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.6 | 17.8 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
